Vox AI Platform

Vox Biomedical is developing a gas chromatography and differential mobility spectrometry (GC-DMS) chemical identification library for volatile organic compounds (VOCs) using a deep neural network approach.

We are seeking investments to help accelerate the development of our proprietary Artificial Intelligence (AI) library, biomarker discovery and initiate marketing efforts.

The Solution

• The Vox breath analyzer uses spectroscopy technology to measure VOCs in the exhaled breath.
• This approach provides improved sensitivity and can distinguish specific biomarkers in breath.
• Vox AI library will enable breath-based biomarker discovery for cancer and infectious diseases.

The Product

The Vox Venturi breath analyzer can be used for a wide range of applications including illicit drugs and disease detection. The subject breathes into a disposable cartridge, and then it is analyzed on-site. 

Business Model

Revenue will be generated from 3 sources:

• Sale of breath analyzer units.
• Software-as-a-service model for the chemical identification library.
• Accessory materials, which include disposable cartridges and achievable filters.

Market Opportunity

• Initial target market will be research labs and hospitals.
• Police and law enforcement market in the U.S.
• Workplace detection market.

Strategy

Vox Biomedical’s initial development efforts are being funded by National Institutes of Health. Based on preliminary positive Phase I results, Vox Biomedical expects  Phase II program for additional AI development and prototyping of the instrument. NIH Phase II funding will be critical to achieving market acceptance, and will significantly accelerate market penetration.